BioDelivery Sciences International, Inc. (BDSI): Price and Financial Metrics

BioDelivery Sciences International, Inc. (BDSI)

Today's Latest Price: $4.30 USD

0.01 (-0.23%)

Updated Jan 19 4:00pm

Add BDSI to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 483 in Biotech

See all "A" rated Strong Buy stocks

BDSI Stock Summary

  • Of note is the ratio of Biodelivery Sciences International Inc's sales and general administrative expense to its total operating expenses; 87.91% of US stocks have a lower such ratio.
  • In terms of twelve month growth in earnings before interest and taxes, Biodelivery Sciences International Inc is reporting a growth rate of -1,694.34%; that's higher than only 1.19% of US stocks.
  • Revenue growth over the past 12 months for Biodelivery Sciences International Inc comes in at 49.25%, a number that bests 89.46% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to BDSI, based on their financial statements, market capitalization, and price volatility, are IVC, AMG, INDO, ECOM, and UFI.
  • Visit BDSI's SEC page to see the company's official filings. To visit the company's web site, go to

BDSI Stock Price Chart Interactive Chart >

Price chart for BDSI

BDSI Price/Volume Stats

Current price $4.30 52-week high $5.98
Prev. close $4.31 52-week low $2.85
Day low $4.28 Volume 1,100,466
Day high $4.40 Avg. volume 1,498,242
50-day MA $4.13 Dividend yield N/A
200-day MA $4.22 Market Cap 434.78M

BioDelivery Sciences International, Inc. (BDSI) Company Bio

BioDelivery Sciences International, Inc. engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company was founded in 1997 and is based in Raleigh, North Carolina.

BDSI Latest News Stream

Event/Time News Detail
Loading, please wait...

BDSI Latest Social Stream

Loading social stream, please wait...

View Full BDSI Social Stream

Latest BDSI News From Around the Web

Below are the latest news stories about Biodelivery Sciences International Inc that investors may wish to consider to help them evaluate BDSI as an investment opportunity.

BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS) Meeting

Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory Outcomes Comparing BELBUCA® to Oxycodone on January 16 from 1:10pm – 2:10pm CTRALEIGH, N.C., Jan. 15, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will present three scientific posters regarding BELBUCA® (buprenorphine buccal film), CIII at the 2021 North American Neuromodulation Society Meeting (NANS) taking place virtually January 15-16, 2021.“We are pleased to be presenting this data at NANS 2021 and sharing this information with the scientific community,” said Thomas Smith, M.D., Chief Medical Officer of BDSI.Data from a placebo-controlled study compared safety outcom...

Yahoo | January 15, 2021

Musculoskeletal Pains Market - Insights On Scope 2025 | Zogenix, Inc., Dainippon Sumitomo Pharma Co., Ltd., BioDelivery Sciences International, Inc.

Global Musculoskeletal Pains Market: Snapshot Musculoskeletal pain is pain that affects bones, muscles, or the various types of connective tissues that hold the two together, such as tendons and ligaments. This type of pain can occur due to overuse or repetitive

OpenPR | January 6, 2021

Are Robust Financials Driving The Recent Rally In BioDelivery Sciences International, Inc.'s (NASDAQ:BDSI) Stock?

BioDelivery Sciences International's (NASDAQ:BDSI) stock is up by a considerable 15% over the past three months. Given...

Yahoo | December 22, 2020

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Insider James Vollins Sells 20,320 Shares

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) insider James Vollins sold 20,320 shares of the firm’s stock in a transaction that occurred on Monday, December 14th. The shares were sold at an average price of $4.46, for a total transaction of $90,627.20. Following the transaction, the insider now owns 20,320 shares in the company, valued at approximately […]

Watchlist News | December 19, 2020

Is BDSI A Good Stock To Buy?

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

Yahoo | December 19, 2020

Read More 'BDSI' Stories Here

BDSI Price Returns

1-mo -5.29%
3-mo 31.50%
6-mo 1.42%
1-year N/A
3-year 59.26%
5-year 14.97%
YTD 2.38%
2020 -33.54%
2019 70.81%
2018 25.42%
2017 68.57%
2016 -63.47%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7539 seconds.